Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus chemotherapy in locally advanced esophageal squamous cell carcinoma
NCT06152978Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Dec 2023
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sintilimab in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Fudan University. Primary endpoint: Event-free survival at 12 months. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06152978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06152978.